Posted by
FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic

FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic

For Immediate Release March 5, 2019 Release The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Because of the risk of serious adverse outcomes resulting […]